Citations

Clear

3030 citation(s) found for "Susan, M".

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasiv
Hendry, Shona , Salgado, Roberto , Gevaert, Thomas, Russell, Prudence A. , John, Tom, Thapa, Bibhusal , Estrada, Mónica V. , González-Ericsson, Paula I. , Solomon, Benjamin , Solinas, Cinzia , Eynden, Gert G. G. M. Van den, Preusser, Matthias , Hainfellner, Johannes A. , Pruneri, Giancarlo , Vingiani, Andrea , Demaria, Sandra , Symmans, Fraser, Nucíforo, Paolo , Comerma, Laura , Thompson, E. Aubrey , Kim, Seong-Rim , Schnitt, Stuart J. , Colpaert, Cécile , Scherer, Stefan, Viale, Giuseppe , Sirtaine, Nicolas , Penault‐Llorca, Frédérique, Sugie, Tomohagu, Fineberg, Susan , Paik, Soonmyung , Richardson, Andrea L., Wang, Yihong , Chmielik, Ewa , Brock, Jane B. , Johnson, Douglas B. , Wienert, Stephan, Bossuyt, Veerle , Michiels, Stefan , Ternès, Nils, Burchardi, Nicole, Klauschen, Frederick , Watson, Peter H. , Nelson, Brad H. , O’Toole, Sandra A., Larsimont, Denis , Wind, Roland de, Curigliano, Giuseppe , André, Fabrice , Vijver, Marc J. van de , Rojo, Federico , Floris, Giuseppe , Bedri, Shahinaz , Sparano, Joseph A. , Rimm, David L. , Kos, Zuzana , Hewitt, Stephen M. , Farshid, Gelareh , Loibl, Sibylle , Allison, Kimberly H. , Adams, Sylvia , Willard‐Gallo, Karen , Gandhi, Leena , Moreira, André L. , Hirsch, Fred R. , Dieci, Maria Vittoria , Urbanowicz, María, Brčić, Iva , Korski, Konstanty, Gaire, Fabien, Koeppen, Hartmut , Lo, Amy, Rebelatto, Marlon C., Steele, Keith E. , Zha, Jiping, Emancipator, Kenneth , Juco, Jonathan, Loi, Sherene , Fox, Stephen B. , Symmans, W. Fraser , John, Thomas , Wang, Yihong , Gonzalez-Ericsson, Paula I , Curigliano, Giuseppe , Sparano, Joseph A , Nelson, Brad H , Preusser, Matthias , André, Fabrice , Symmans, W Fraser , Loi, Sherene , John, Tom, Christie, Michael , Van de Vijver, Koen , Sanders, Melinda E. , Allory, Yves , Lakhani, Sunil R. , Sotiriou, Christos P. , Ignatiadis, Michail , Badve, Sunil , Pierce, Robert Hamilton , Srinivasan, Ashok , Richardson, Andrea L. , Balko, Justin M. , Luen, Stephen James , Savas, Peter Stephen , Criscitiello, Carmen , Lacroix‐Triki, Magali , Nielsen, Torsten O. , Singh, Baljit , Tung, Nadine , Horlings, Hugo , Lo, Amy, Giltnane, Jennifer Margaret , Denkert, Carsten , Reis‐Filho, Jorge S. , Pruneri, Giancarlo , Rimm, David , Dieci, Maria Vittoria , Nuciforo, Paolo , Solomon, Benjamin J

Mayo Clinic

Advances in Anatomic Pathology | August 2, 2017 | Volume: 24 | Issue: 5 | Pages: 235-251

10.1097/pap.0000000000000162 | PMID 28777142 Get It

Assessment of tumor-infiltrating lymphocytes (TILs) in histopathologic specimens can provide important prognostic information in diverse solid tumor types, and may also be of value in predicting response to treatments. However, implementation as a routine clinical biomarker has not yet been achieved. As successful use of immune checkpoint inhibitors and other forms of immunotherapy become a clinical reality, the need for widely applicable, accessible, and reliable immunooncology biomarkers is clear. In part 1 of this review we briefly discuss the host immune response to tumors and different approaches to TIL assessment. We propose a standardized methodology to assess TILs in solid tumors on hematoxylin and eosin sections, in both primary and metastatic settings, based on the International Immuno-Oncology Biomarker Working Group guidelines for TIL assessment in invasive breast carcinoma. A review of the literature regarding the value of TIL assessment in different solid tumor types follows in part 2. The method we propose is reproducible, affordable, easily applied, and has demonstrated prognostic and predictive significance in invasive breast carcinoma. This standardized methodology may be used as a reference against which other methods are compared, and should be evaluated for clinical validity and utility. Standardization of TIL assessment will help to improve consistency and reproducibility in this field, enrich both the quality and quantity of comparable evidence, and help to thoroughly evaluate the utility of TILs assessment in this era of immunotherapy.
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinoma
Hendry, Shona , Salgado, Roberto , Gevaert, Thomas, Russell, Prudence A. , John, Tom, Thapa, Bibhusal , Estrada, Mónica V. , González-Ericsson, Paula I. , Sanders, Melinda, Solomon, Benjamin , Solinas, Cinzia , Eynden, Gert G. G. M. Van den, Preusser, Matthias , Hainfellner, Johannes A. , Pruneri, Giancarlo , Vingiani, Andrea , Demaria, Sandra , Symmans, Fraser, Nucíforo, Paolo , Comerma, Laura , Thompson, E. Aubrey , Kim, Seong-Rim , Schnitt, Stuart J. , Colpaert, Cécile , Scherer, Stefan, Viale, Giuseppe , Sirtaine, Nicolas , Sugie, Tomohagu, Fineberg, Susan , Paik, Soonmyung , Richardson, Andrea L., Wang, Yihong , Chmielik, Ewa , Brock, Jane, Johnson, Douglas B. , Wienert, Stephan, Bossuyt, Veerle , Michiels, Stefan , Ternès, Nils, Burchardi, Nicole, Savas, Peter, Klauschen, Frederick , Watson, Peter H. , Nelson, Brad H. , O’Toole, Sandra A., Larsimont, Denis , Wind, Roland de, Curigliano, Giuseppe , André, Fabrice , Vijver, Marc J. van de , Rojo, Federico , Floris, Giuseppe , Bedri, Shahinaz , Sparano, Joseph A. , Rimm, David L. , Kos, Zuzana , Hewitt, Stephen M. , Farshid, Gelareh , Loibl, Sibylle , Allison, Kimberly H. , Adams, Sylvia , Willard‐Gallo, Karen , Gandhi, Leena , Hirsch, Fred R. , Dieci, Maria Vittoria , Urbanowicz, María, Brčić, Iva , Korski, Konstanty, Gaire, Fabien, Koeppen, Hartmut , Lo, Amy, Rebelatto, Marlon C., Steele, Keith E. , Zha, Jiping, Emancipator, Kenneth , Juco, Jonathan, Loi, Sherene , Fox, Stephen B. , Symmans, W. Fraser , John, Thomas , Wang, Yihong , Gonzalez-Ericsson, Paula I , Curigliano, Giuseppe , Sparano, Joseph A , Nelson, Brad H , Preusser, Matthias , André, Fabrice , Symmans, W Fraser , Loi, Sherene , John, Tom, Christie, Michael , Van de Vijver, Koen , Allory, Yves , Lakhani, Sunil R. , Sotiriou, Christos P. , Ignatiadis, Michail , Badve, Sunil , Pierce, Robert Hamilton , Penault-Llorca, Frederique Madeleine , Srinivasan, Ashok , Richardson, Andrea L. , Balko, Justin M. , Luen, Stephen James , Savas, Peter Stephen , Criscitiello, Carmen , Lacroix‐Triki, Magali , Nielsen, Torsten O. , Singh, Baljit , Tung, Nadine , Horlings, Hugo , Moreira, Andre M. , Lo, Amy, Giltnane, Jennifer Margaret , Denkert, Carsten , Reis‐Filho, Jorge S. , Pruneri, Giancarlo , Rimm, David , Dieci, Maria Vittoria , Nuciforo, Paolo , Solomon, Benjamin J

Mayo Clinic

Advances in Anatomic Pathology | August 2, 2017 | Volume: 24 | Issue: 6 | Pages: 311-335

10.1097/pap.0000000000000161 | PMID 28777143 Get It

Assessment of the immune response to tumors is growing in importance as the prognostic implications of this response are increasingly recognized, and as immunotherapies are evaluated and implemented in different tumor types. However, many different approaches can be used to assess and describe the immune response, which limits efforts at implementation as a routine clinical biomarker. In part 1 of this review, we have proposed a standardized methodology to assess tumor-infiltrating lymphocytes (TILs) in solid tumors, based on the International Immuno-Oncology Biomarkers Working Group guidelines for invasive breast carcinoma. In part 2 of this review, we discuss the available evidence for the prognostic and predictive value of TILs in common solid tumors, including carcinomas of the lung, gastrointestinal tract, genitourinary system, gynecologic system, and head and neck, as well as primary brain tumors, mesothelioma and melanoma. The particularities and different emphases in TIL assessment in different tumor types are discussed. The standardized methodology we propose can be adapted to different tumor types and may be used as a standard against which other approaches can be compared. Standardization of TIL assessment will help clinicians, researchers and pathologists to conclusively evaluate the utility of this simple biomarker in the current era of immunotherapy.
Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes
Mahar, Alyson , Compton, Carolyn C. , Halabi, Susan , Hess, Kenneth R. , Weiser, Martin R. , Groome, Patti A. , Mahar, Alyson L , Compton, Carolyn, Halabi, Susan

Mayo Clinic

Journal of Surgical Oncology | August 2, 2017 | Volume: 116 | Issue: 8 | Pages: 969-982

10.1002/jso.24774 | PMID 28767139 Get It

Integrating diverse types of prognostic information into accurate, individualized estimates of outcome in colorectal cancer is challenging. Significant heterogeneity in colorectal cancer prognostication tool quality exists. Methodology is incompletely or inadequately reported. Evaluations of the internal or external validity of the prognostic model are rarely performed. Prognostication tools are important devices for patient management, but tool reliability is compromised by poor quality. Guidance for future development of prognostication tools in colorectal cancer is needed.
Abstract CT158: Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Fraser, Graeme , Brown, Jennifer R. , Byrd, John C. , Dilhuydy, Marie‐Sarah, Jaeger, Ulrich, Moreno, Carol , Chanan‐Khan, Asher , Mahler, Michelle, Salman, Mariya, Cheng, Mei, Londhe, Anil, Ninomoto, Joi , Howes, Angela, James, Danelle F. , Hallek, Michael , Byrd, John C. , Kipps, Thomas J. , Coutré, Steven , Barrientos, Jacqueline C. , Barr, Paul M. , O’Brien, Susan , Devereux, Stephen , Cramer, Paula , Stilgenbauer, Stephan , Byrd, John C

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: CT158-CT158

10.1158/1538-7445.am2017-ct158 Get It

Abstract Background: Patients (pts) with CLL/SLL who use unmutated IGHV (u-CLL) have a less favorable outcome with standard chemotherapy than pts who use mutated IGHV (m-CLL). Ibrutinib (ibr) inhibits B-cell receptor signaling through Bruton’s tyrosine kinase and has robust clinical activity against CLL. This integrated analysis of 3 phase 3 studies examined the impact of IGHV status on ibr- and comparator (comp)-treated pts. Methods: Pooled data from 3 studies of ibr (420 mg/d) in CLL/SLL pts (RESONATE: relapsed/refractory [R/R] pts, ibr vs ≤ 24 weeks ofatumumab; RESONATE-2: treatment-naïve [TN] pts ≥ 65 yrs of age [no del17p], ibr vs ≤ 12 cycles chlorambucil; HELIOS: R/R pts [no del17p], ≤ 6 cycles bendamustine-rituximab with ibr vs placebo) were analyzed by IGHV status. Analyses included Kaplan-Meier method (overall survival [OS]; progression-free survival [PFS]); log-rank test (group comparisons); and Cox multivariate analysis (prognostic factors; Table). Results: For 491 ibr- (366 u-CLL, 125 m-CLL) and 494 comp-treated (351 u-CLL, 143 m-CLL) pts with IGHV data, baseline characteristics were similar for u-CLL vs m-CLL, except for the proportions of pts who were TN (17 vs 31%), had bulky disease (60 vs 37%), or had CLL cells with del11q (32 vs 16%). Median follow up was 21.4 mos for ibr and 20.6 mos for comp. PFS and OS were similar for u-CLL and m-CLL ibr-treated pts; u-CLL had poorer outcomes than m-CLL in comp-treated pts, which remained after adjustment for prognostic factors (Table). Ibr treatment was more effective than comp regardless of IGHV status. Incidence of adverse events (AEs) was similar between groups. For ibr vs comp pts (u-CLL/m-CLL): serious AEs: 49% (50%/47%) vs 36.5% (37%/35%); AEs that led to discontinuation: 12% (11%/15%) vs 13% (13%/14%); death within 30 days of last dose: 5% (6%/3%) vs 5% (6%/2%). Conclusions: U-CLL was an adverse predictor of outcome for comp-treated, but not for ibr-treated pts. Table.Efficacy Outcomes in Ibr- and Comparator-Treated Patients by IGHV Mutation StatusIbrutinib (N=491)Comparator (N =494)u-CLL (n=717)m-CLL (n=268)u-CLL(n=366): m-CLL(n=125)u-CLL(n=351): m-CLL(n=143)Ibr(n=366): Comp(n=351)Ibr (n=125): Comp (n=143)PFS24-month rate HR78%:81%10%:32%78%:10%81%:32%0.93a1.99a0.12b0.21bp = 0.78p < 0.0001p < 0.0001p <0.0001Adjusted HRc1.02a1.94a0.11b0.17bp = 0.93p < 0.0001p < 0.0001p < 0.0001OS24-month rate HR88%:89%78%:87%88%:78%89%:87%0.95a1.96a0.49b0.85b,ep = 0.86p = 0.02p < 0.01p = 0.66Adjusted HRc1.21a2.10a0.49bNAp =0.57p = 0.01p < 0.001Response ratesu-CLLm-CLLu-CLLm-CLLIbrCompIbrCompORR, %d8990475189479051p = 0.96p = 0.36p < 0.0001p < 0.0001CR, %d221546224156p = 0.10p = 0.44p < 0.0001p = 0.01CI, confidence interval; CR, complete response; HR, hazard ratio; ORR, overall response rate; NA, not applicable. aHR < 1 favors unmutated. bHR < 1 favors ibrutinib. cMultivariate Cox model adjusted for age, sex, current Rai stage, baseline ECOG performance status score, del11q, del17p, number of prior therapies, and cytopenias. dp value is from a Cochran-Mantel-Haenszel chi-square test. eInsufficient number of events prevents meaningful analysis, only 13 and 16 events observed in ibr and comp groups, respectively, and 46 (32%) pts in comp arm crossed over to ibr arm; interpret results with caution. Citation Format: Thomas J. Kipps, Graeme Fraser, Steven Coutre, Jennifer R. Brown, Jacqueline C. Barrientos, Paul M. Barr, John C. Byrd, Susan M. O'Brien, Marie-Sarah Dilhuydy, Stephen Devereux, Ulrich Jaeger, Carol Moreno, Paula Cramer, Stephan Stilgenbauer, Asher A. Chanan-Khan, Michelle Mahler, Mariya Salman, Mei Cheng, Anil Londhe, Joi Ninomoto, Angela Howes, Danelle James, Michael Hallek. Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr CT158. doi:10.1158/1538-7445.AM2017-CT158
Abstract 4290: A study in locus heterogeneity: Targeted sequencing analysis of 6q reveals multiple significant loci as the source of a previous linkage peak in familial lung cancer
Moiz, Bilal A., Middlebrooks, Candace D., Mandal, Diptasri , Gaba, Colette , Yang, Ping , Li, Yafang , Kupert, Elena, Anderson, Marshall W., Schwartz, Ann G. , Musolf, Anthony M. , Simpson, Claire L. , Andrade, Mariza de , You, Ming , Pinney, Susan M. , Amos, Christopher I. , Bailey‐Wilson, Joan E.

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 4290-4290

10.1158/1538-7445.am2017-4290 Get It

Abstract Lung cancer is the leading cancer-related cause of death in the United States. We had previously performed multipoint linkage analysis on families with a strong family history of lung cancer and found significant linkage to the 6q25 region. In order to find the source of that linkage signal, we performed targeted sequencing 6q23-6q27 on 75 individuals from the 9 most highly linked families. We performed two types of parametric linkage analysis, using an autosomal dominant mode of inheritance with 10% penetrance for carriers and a 1% phenocopy rate using a disease allele frequency of 1%. The first type was a two-point analysis using an Elston-Stewart algorithm. This approach did not lead to any genome-wide significant results but demonstrated significant heterogeneity throughout the nine families.In an effort to recover the power from the original multipoint analysis, we performed a regional linkage analysis using SEQLinkage and MERLIN. SEQLinkage built regional haplotypes that corresponded to a gene or an intergenic region - the regions were based on a customized map of our design. The regional markers were multiallelic which allowed for greater information content and were similar to the microsatellites that were used in the original multipoint analysis. The regional markers were then analyzed in a two-point linkage analysis via MERLIN. This allowed us to identify two genome-wide significant signals at PACRG-AS1 at 6q26 (HLOD = 3.4) and SAMD5 at 6q24 (3.3). The PACRG-AS1 is novel, though it is associated with the known lung cancer gene PARK2. SAMD5 may be involved in lung cancer cell proliferation. The heterogeneity of the two signals was particularly interesting. The PACRG-AS1 was driven primarily by two families. The SAMD5 marker was not being strongly driven by any of the families and appears to be a small cumulative effect across the nine families. In addition, several families have large, but non-significant LOD scores at other loci across the region. This further reinforces the locus heterogeneity within the region, and it is likely that our two significant signals here are not the only variants affecting the phenotype. We further attempted to localize the signals by running SEQLinkage using a custom map where genes are broken into exons and introns. Though this resulted in no significant markers, the highest signal was located in the intronic region of SAMD5 (HLOD = 3) and several other suggestive signals were localized to intronic regions of good candidate genes like SASH1 and ARID1B. Examination of predicted effects of the candidate regulatory variants using eQTL databases is ongoing. This is a region full of promising candidates, and it is likely that the two significant signals found here are just part of many that could be affecting lung cancer risk. We plan to do further analysis within the individual families to elucidate any more genes affecting this signal. Citation Format: Anthony M. Musolf, Claire L. Simpson, Bilal A. Moiz, Candace Middlebrooks, Mariza de Andrade, Diptasri Mandal, Colette Gaba, Ping Yang, Yafang Li, Ming You, Elena Y. Kupert, Marshall W. Anderson, Ann G. Schwartz, Susan M. Pinney, Christopher I. Amos, Joan E. Bailey-Wilson. A study in locus heterogeneity: Targeted sequencing analysis of 6q reveals multiple significant loci as the source of a previous linkage peak in familial lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4290. doi:10.1158/1538-7445.AM2017-4290
Abstract 4268: Familial lung cancer is significantly linked to cancer-associated genes on five chromosomes
Mandal, Diptasri , Gaba, Colette G., You, Ming , Kupert, Elena, Anderson, Marshall W., Schwartz, Ann G. , Bailey‐Wilson, Joan E. , Musolf, Anthony M. , Simpson, Claire L. , Andrade, Mariza de , Gaba, Colette , Yang, Ping , Pinney, Susan M. , Amos, Christopher I.

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 4268-4268

10.1158/1538-7445.am2017-4268 Get It

Abstract Lung cancer (LC) is the leading cancer killer of Americans; an estimated 158,000 people will die in the U.S. from LC in 2016. While it is well-known that LC risk is affected by the environment, particularly tobacco smoking, there is a substantial genetic risk to LC also. We examined genotype data from Illumina HumanCore-12v1-0 array (297,000 SNPs) on 175 individuals in 25 extended families with a strong history of LC recruited by the Genetic Epidemiology of Lung Cancer Consortium. The purpose of this study is to determine which families are segregating a high-penetrance genetic risk haplotype so that the most informative families can be selected for DNA sequencing studies. Quality control was performed to remove SNPs and individuals with greater than 1% missingness as well as monomorphic SNPs. SNPs with Mendelian errors in more than one family were dropped. Identity-by-descent values were calculated to confirm correct familial relationships; 1 individual was dropped. After quality control we were left with approximately 245,000 SNPs for analysis. We performed three types of parametric linkage analyses using an autosomal dominant model with 40% penetrance in carriers and 1% penetrance in non-carriers. A disease allele frequency of 0.01 was used. Standard single variant two-point analysis between the disease and each marker was performed using TwoPointLods. Multipoint linkage analysis was performed using SimWalk2. We also performed regional-based linkage analyses using SEQLinkage and MERLIN. SEQLinkage builds a multiallelic regional marker (similar to a microsatellite) that corresponds to a gene or a portion of a gene. Two-point linkage analyses were then performed on the regional markers using MERLIN. We identified five loci that were genome-wide significant (HLOD score ≥ 3.3) from the regional-based linkage analyses on 18p11.23 (HLOD = 4.1), 2p22.2 (3.9), 14q13.1 (3.7), 16p13.1 (3.4), and 20q13.11 (3.4). It is particularly exciting that the scores centered on prospective cancer genes. Our highest score was centered on PTPRM, a protein tyrosine phosphatase on chromosome 18 that has been implicated as a LC oncogene. The signal on 20q13 also centered on another protein tyrosine phosphatase (PTPRT) that has been shown to be mutated in LC cells. The source of the signal on 16p13 was RNA binding protein RBFOX1, which has been shown to be deleted in LC cell lines and the source of the signal on 2p22 was LRP1B, a LDL receptor-related protein that is often inactivated in LC cells. The source of the final signal on 14q13 was NPAS3, a transcription factor that is a tumor suppressor in brain tumors. It should be noted that all previous evidence linking these genes to cancer was based on somatic mutations; this is the first time any of these genes has been shown to be significantly linked to germline disease risk in a family-based study. We plan to perform targeted sequencing on the linked regions to elucidate the exact causal variant. Citation Format: Joan E. Bailey-Wilson, Anthony M. Musolf, Claire L. Simpson, Mariza de Andrade, Diptasri Mandal, Colette G. Gaba, Ping Yang, Ming You, Elena Y. Kupert, Marshall W. Anderson, Ann G. Schwartz, Susan M. Pinney, Christopher I. Amos. Familial lung cancer is significantly linked to cancer-associated genes on five chromosomes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4268. doi:10.1158/1538-7445.AM2017-4268
Abstract 4267: Association of polygenic risk scores and family history with the risk of chronic lymphocytic leukemia (CLL)
Kleinstern, Geffen , Sanjosé, Sílvia de , Camp, Nicola J. , Call, Timothy G. , Liebow, Mark , Robinson, Dennis P. , Cunningham, Julie L. , Benavente, Yolanda , Monnereau, Alain , Spinelli, John, Vajdic, Claire M. , Kay, Neil E. , Cerhan, James R. , Slager, Susan L.

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 4267-4267

10.1158/1538-7445.am2017-4267 Get It

Abstract Background Thirty-four single nucleotide polymorphisms (SNPs) are associated with CLL risk to-date. Moreover, family history (FH) of hematological malignancy has been consistently found to be associated with CLL, with an 8.5-fold increased risk of CLL among first-degree relatives. However, there has not been an evaluation of the interactive effects among genetic factors and FH with CLL risk. Methods We pooled data from 8 CLL case-control studies within the InterLymph Consortium (1499 CLL cases and 2601 controls). We computed a polygenic risk score (PRS), a weighted average of the number of risk alleles across the 34 SNPs, with the weights being the log of the previously reported odds ratio (OR) for each SNP. We categorized the PRS by quintiles using the cutoff points based on the distribution of all InterLymph controls (N=8228). Self-reported FH data was available for 60% of cases and 73% of controls. FH was defined as any hematological malignancy in one or more first-degree relative. Logistic regression was used to estimate ORs and 95% confidence intervals (CIs) adjusted for age, sex, socioeconomic status and study. Results The median age at diagnosis of CLL was 63 years and median age of consent was 60 years in the controls. 67% were male in CLL cases and 57% in controls. As expected, FH was associated with CLL risk (OR= 2.14, CI= 1.60-2.86). The median PRS in the cases was 0.40 and in the controls was -0.36 with the frequency of CLL cases in the upper PRS quintile as 48% while in the lowest quintile only 6%. The PRS was strongly associated with CLL risk (OR= 2.90, CI= 2.35-3.56 for upper versus middle quintile). When jointly modeling FH with PRS, a significant interaction was observed (P=0.03). When stratifying by FH, the upper quintile of the PRS had an 11.8-fold (CI= 3.97-34.8) increased risk relative to those in the middle quintile in the FH+ strata, while a 3.11-fold (CI= 2.35-4.10) increased risk was observed in the FH- strata. Conclusions Our data suggest that the PRS has a strong association with CLL risk and this association varies with FH status. Among those with FH-, the risk of CLL was 3-fold for those with many inherited variants while the CLL risk was much higher than that in those with a FH+. Studies are needed to see whether this PRS stratifies risk among those with monoclonal B-cell lymphocytosis, the CLL precursor condition that affects 5-7% of the general population. Citation Format: Geffen Kleinstern, Silvia de Sanjosé, Nicola Camp, Claire M. Vajdic, Timothy G. Call, Mark Liebow, Dennis Robinson, Neil E. Kay, Julie Cunningham, Yolanda Benavente, Alain Monnereau, John Spinelli, James R. Cerhan, Susan L. Slager. Association of polygenic risk scores and family history with the risk of chronic lymphocytic leukemia (CLL) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4267. doi:10.1158/1538-7445.AM2017-4267
Abstract 4265: Risks of familial breast cancer associated with known and proposed breast cancer susceptibility genes
Slavin, Thomas P., Lilyquist, Jenna , Ravichandran, Vignesh , Maria, Ann, Moore, Raymond M. , Wubbenhorst, Brad, Wenz, Brandon M., D’Andrea, Kurt , Peterlongo, Paolo, Offit, Kenneth , Nathanson, Katherine L. , Peterlongo, Paolo , Maxwell, Kara N. , Vijai, Joseph , Neuhausen, Susan L. , Hart, Steven N. , Thomas, Tinu , Schrader, Kasmintan A. , Hu, Chunling , Domchek, Susan M. , Robson, Mark E. , Radice, Paolo , Ford, James M. , Garber, Judy E. , Szabo, Csilla I. , Couch, Fergus J. , Weitzel, Jeffrey N. , Peterlongo, Paolo , Nathanson, Katherine L , Ravichandran, Vignesh

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 4265-4265

10.1158/1538-7445.am2017-4265 Get It

Abstract A better understanding of gene-specific risks for development of breast cancer will lead to improved screening, prevention, and therapeutic strategies for individuals identified to carry germline mutations. We performed targeted massively-parallel sequencing to identify mutations and large genomic rearrangements in 26 known or proposed breast cancer susceptibility genes in 2134 BRCA-negative women with familial breast cancer (FBC). A case-control analysis was performed comparing the frequency of internally classified mutations identified in FBC cases to that in non-Finnish European controls from the Exome Aggregation Consortium (ExAC) excluding samples from The Cancer Genome Atlas. Including large genomic rearrangements, mutations were identified in 8.2% of FBC cases compared to 6.2% of ExAC controls, including mutations in high-penetrance genes (0.6% in cases vs. 0.1% in controls), moderate-penetrance genes (3.7% vs 1.7%), and seven cases with two mutations (0.3%). The remainder of FBC cases and ExAC controls had mutations in proposed breast cancer genes (1.6% of cases vs 2.4% of controls), Lynch syndrome genes (0.5% vs. 0.5%) or were heterozygous MUTYH carriers (1.5% vs. 1.5%). Case-control analysis demonstrated significant associations with FBC for ATM, PALB2, and TP53 mutations (OR>3.0, p<10-4), BARD1 mutations (OR=3.2, p=0.012), and CHEK2 truncating mutations (OR=1.6, p=0.041). Our results therefore demonstrate that only approximately 4% of BRCA1/2 negative FBC patients have mutations in genes definitively associated with breast cancer at this time. Large case-control studies are needed to fully evaluate the breast cancer risks associated with moderate penetrance and proposed breast cancer susceptibility genes. Citation Format: Kara N. Maxwell, Thomas Paul Slavin, Jenna M. Lilyquist, Joseph Vijai, Susan L. Neuhausen, Steven N. Hart, Vignesh Ravichandran, Tinu Thomas, Ann Maria, Kasmintan A. Schrader, Raymond Moore, Chunling Hu, Brad Wubbenhorst, Brandon M. Wenz, Kurt D'Andrea, Susan M. Domchek, Mark E. Robson, Paulo Peterlongo, Paolo Radice, James M. Ford, Judy E. Garber, Csilla Szabo, Kenneth Offit, Katherine L. Nathanson, Fergus J. Couch, Jeffrey N. Weitzel. Risks of familial breast cancer associated with known and proposed breast cancer susceptibility genes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4265. doi:10.1158/1538-7445.AM2017-4265
Abstract 1318: A genome-wide association study of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma demonstrates association with chromosome 6
McMaster, Mary L. , Berndt, Sonja I. , Li, Shengchao A. , Chung, Charles C., Zhu, Bin , Burdette, Laurie , Brown, Elizabeth E. , Ekström‐Smedby, Karin, Hjalgrim, Henrik , McKay, James , Monnereau, Alain , Nieters, Alexandra, Rothman, Nathaniel , Skibola, Christine F., Smith, Alex, Hicks, Belynda , Goldin, Lynn R. , Caporaso, Neil E., Slager, Susan L. , Vijai, Joseph , Birmann, Brenda M. , Cerhan, James R. , Kleinstern, Geffen , Link, Brian K. , Morton, Lindsay M. , Rothman, Nathaniel , Teras, Lauren R. , Vajdic, Claire M. , Vermeulen, Roel

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 1318-1318

10.1158/1538-7445.am2017-1318 Get It

Abstract Waldenström macroglobulinemia (WM) is a unique subset of lymphoplasmacytic lymphoma (LPL) that is defined by the presence of an LPL infiltrate in the bone marrow together with a monoclonal IgM protein in the serum. A somatic activating mutation, MYD88 L265P, occurs in 85+% of WM and in 25%-50% of patients with the precursor condition, IgM monoclonal gammopathy of undetermined significance (MGUS); however, germline MYD88 mutations have not been observed in WM patients, and the genetic basis for WM predisposition remains undefined. To identify novel WM susceptibility loci we conducted a two-stage genome-wide association study (GWAS) in over 450 WM cases and 4300 controls of European ancestry. Discovery (stage 1) included 217 WM cases (40% familial) and 3798 controls genotyped on the Illumina Omni Express or Illumina Omni2.5 platforms following standard quality control procedures. The genotyped data were imputed using the Haplotype Reference Consortium panel as a reference and analyzed using logistic regression. In stage 1, we identified three loci on chromosomes 6, 14 and 3 significantly associated (P<5.0x10-8) with risk of WM. Eleven promising SNPs in these and other suggestive loci (P<5.0x10-7) were selected for replication (stage 2) in 269 WM or LPL cases (4% familial) and 571 controls, and genotyping was conducted using standard methods on Taqman and Sequenom platforms or Sanger sequencing (1 SNP). Preliminary results confirm replication of the chromosome 6 locus. Stratification on familial status will illuminate the contribution of familial disease. These results will provide insight into the underlying genetic basis of WM susceptibility. Citation Format: Mary L. McMaster, Sonja I. Berndt, Shengchao A. Li, Susan Slager, Joseph Vijai, Charles C. Chung, Bin Zhu, Laurie Burdette, Brenda Birmann, Elizabeth E. Brown, James R. Cerhan, Karin Ekstrom-Smedby, Henrik Hjalgrim, Geffen Kleinstern, Brian K. Link, James McKay, Alain Monnereau, Lindsay M. Morton, Alexandra Nieters, Nathaniel Rothman, Christine F. Skibola, Alex Smith, Lauren R. Teras, Claire M. Vajdic, Roel Vermeulen, Belynda Hicks, Lynn R. Goldin, Neil E. Caporaso. A genome-wide association study of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma demonstrates association with chromosome 6 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1318. doi:10.1158/1538-7445.AM2017-1318
Genome Scan for Linkage to Asthma Using a Linkage Disequilibrium‐lod Score Test
Jiang, Yanming, Sleger, Susan L., Huang, Jian

Mayo Clinic

Genetic Epidemiology | July 28, 2017 | Volume: 21 | Issue: S1 | Pages: No page available

10.1002/gepi.2001.21.s1.s303 | PMID 11793688 Get It

We report a genome‐wide linkage study of asthma on the German and Collaborative Study on the Genetics of Asthma (CSGA) data. Using a combined linkage and linkage disequilibrium test and the nonparametric linkage score, we identified 13 markers from the German data, 1 marker from the African American (CSGA) data, and 7 markers from the Caucasian (CSGA) data in which the p‐values ranged between 0.0001 and 0.0100. From our analysis and taking into account previous published linkage studies of asthma, we suggest that three regions in chromosome 5 (around D5S418, D5S644, and D5S422), one region in chromosome 6 (around three neighboring markers D6S1281, D6S291, and D6S1019), one region in chromosome 11 (around D11S2362), and two regions in chromosome 12 (around D12S351 and D12S324) especially merit further investigation. © 2001 Wiley‐Liss, Inc.